Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
SEATTLE, Feb. 14, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of universal donor cellular therapies for the treatment of patients with blood cancers, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Dr. Colleen Delaney, Nohla’s Scientific Founder and Chief Medical Officer, is scheduled to present on Tuesday, March 7th at 2:00pm ET.
Dr. Delaney’s presentation will provide an overview of the Company’s ex vivo expansion platform, which enables expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). In addition, Dr. Delaney will profile Nohla’s two lead programs evaluating the ability of these products to reduce infection and other complications of neutropenia in multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
About Nohla Therapeutics
Nohla Therapeutics Inc. (Nohla) is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with life threatening blood cancers. The Company is leveraging a platform developed over the past two decades at Fred Hutchinson Cancer Research Center which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). Nohla is evaluating the ability of these “off-the-shelf” cryopreserved expanded cell products to reduce infection and other complications of neutropenia in several clinical settings including two lead programs involving multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). Nohla is supported by top-tier healthcare dedicated institutional investors including ARCH Venture Partners, 5AM Ventures, and Jagen Group.
For more information, please contact: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Esther Cuno Director, Corporate Communications +1 206 519 5313 [email protected]
